Company Securities Exchange Announcements

2020 ASX Announcements

Change of Director's Notice (26/11/20)

Immuron receives AUD $358,280 R&D tax concession refund (24/11/20)

708A notice (18/11/20)

Appendix 3G (17/11/20)

Change of Director's Interest Notivce (x5) (17/11/20)

Change in substantial holding (16/11/20)

Appendix 2A (13/11/20)

Appendix 3G (13/11/20)

Proposed Issue of Securities (13/11/20)

US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine (9/11/20) 

Results of Meeting (29/10/20)

2020 AGM Presentation (29/10/20)

Immuron filed XBRL data with the SEC (29/10/20)

Form 20-F filed with the SEC (29/10/20)

Change in substantial holding (19/10/20)

Immuron Travelers' Diarrhea market update (13/10/20)

Time of AGM clarification (30/09/20)

Corporate Governance Statement (25/09/20)

Notice of Annual General Meeting/Proxy Form (25/09/20)

Appendix 4G (25/09/20)

Annual Report to shareholders (25/09/20)

Change in substantial holding (16/09/20)

Change in substantial holding (04/09/20)

Appendix 4E and 2020 Financial Report (01/09/20) 

Change in substantial holding (28/08/20) 

Change of Director's Interest Notice (PA&SA) (21/08/20)

Change in substantial holding (21/08/20)

Change in substantial holding (19/08/20)

Change in substantial holding (12/08/20)

Change in substantial holding (05/08/20)

Change in substantial holding (31/07/20)

Appendix 2A and 708A Notice (29/07/20)

Proposed issue of Securities – IMC (29/07/20)

Change in substantial holding (28/07/20)

Proposed issue of Securities - IMC (27/07/20)

US SEC Form 6-K Filing (24/07/20) 

Prospectus Supplement (24/07/20)

Appendix 2A and 708A Notice (24/07/20)

Closing of US$20 Million Registered Direct Offering (24/07/20) 

Proposed issue of Securities – IMC (23/07/20) 

Immuron Announces US$20.0 Million Registered Direct Offering (22/07/20) 

Immuron Reports Neutralizing activity Against SARS-CoV-2 (21/07/20)

US DoD Receives FDA Guidance on clinical development plans (20/07/20)  

Appendix 3G (03/07/20)

Appendix 2A and 708A notice (03/07/20)

Proposed issue of Securities – IMC (01/07/20)

Change in substantial holding (26/06/20)

Change in substantial holding (25/06/20)

Change of Director's Interest Notice (RA) (23/06/20)

Change of Director's Interest Notice (DP) (23/06/20)

Appendix 2A and 708A notice (23/06/20)

Change in substantial holding (23/06/20)

Proposed issue of Securities – IMC (22/06/20)

Proposed issue of Securities – IMC (22/06/20)

Change in substantial holding (22/06/20)  

IMC & CSIRO to produce oral therapeutic for DoD evaluation (19/06/20)

Change in substantial holding (GL) (19/06/20)

Change of Director's Interest Notice PA (19/06/20)

Change in substantial holding (19/06/20)

Change in substantial holding (18/06/20)

Change in substantial holding (17/06/20)

Appendix 2A and 708A notice (16/06/20)

Ceasing to be a substantial holder (16/06/20)

Change in substantial holding (16/06/20)

Proposed issue of Securities – IMC (15/06/20)  

Change of Director's Interest Notice (DP) (12/06/20)

Response to ASX Price Query (10/06/20)

Pause in Trading (10/06/20)  

US Defense requests FDA meeting (09/06/20)

Immuron Board Relinquish Cash Payment of Fees (27/04/20)  

Immuron Global Sales Up 60% (20/04/20)  

Final Director's Interest Notice (GJ) (26/03/20) 

Resignation of Managing Director and cuts amid Covid19 (25/03/20)  

Immuron Provides Update on First Half of FY20 Results (02/03/20)

Half Yearly Report and Accounts (26/02/20)

Change in substantial holding (12/02/20)

North American Travelan sales up 98% to Dec 2019 (28/01/20)

Change of Share Registry (20/01/20)

Immuron CEO to present at Biotech Conference in SFO (08/01/20)

To view Immuron ASX Market Announcements for all years prior to 2020, please click here and enter Immuron's company code IMC.